drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, second-generation CD19-directed CAR T-cell therapy; patient T cells are engineered to express a CD19-specific chimeric antigen receptor with costimulation to kill CD19+ leukemic B cells. Expected on-target effect includes B-cell aplasia.
nci_thesaurus_concept_id
C175465
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a CD19-specific chimeric antigen receptor containing 4-1BB costimulatory and CD3zeta signaling domains. Upon binding CD19 on B-lineage cells, the CAR T cells activate, proliferate, release cytotoxic mediators, and kill CD19+ leukemic cells, with expected on-target B-cell aplasia.
drug_name
CNCT19
nct_id_drug_ref
NCT05667506